Evidence map›Paper›PMID 32362166›Full record

Trial reportCirculation. Heart failure2020

Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial.

Brahim Redouane, Stephen J Greene, Marat Fudim, Muthiah Vaduganathan, Andrew P Ambrosy, Jie-Lena Sun, Adam D DeVore, Steven E McNulty, Robert J Mentz, Adrian F Hernandez and 6 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Heart failure, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01800968. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01800968 phase2completed

Functional Impact of GLP-1 for Heart Failure Treatment

Ran2013Enrolled300Registered outcomes19Posted comparisons19ConditionsAcute Heart FailureArmsliraglutide, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Drug Therapies for Diabetes.International journal of molecular sciences · 2023
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Brahim RedouaneMcGill University Health Centre, McGill University, Montreal, QC, Canada (B.R., A.S.).
Stephen J GreeneDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.J.G., M.F., J.-L.S., A.D.D, S.E.M., R.J.M., A.F.H., G.M.F.).
Marat FudimDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.J.G., M.F., J.-L.S., A.D.D, S.E.M., R.J.M., A.F.H., G.M.F.).
Muthiah VaduganathanBrigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (M.V.).
Andrew P AmbrosyDivision of Cardiology, The Permanente Medical Group, San Francisco, CA (A.P.A.).
Jie-Lena SunDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.J.G., M.F., J.-L.S., A.D.D, S.E.M., R.J.M., A.F.H., G.M.F.).
Adam D DeVoreDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.J.G., M.F., J.-L.S., A.D.D, S.E.M., R.J.M., A.F.H., G.M.F.).
Steven E McNultyDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.J.G., M.F., J.-L.S., A.D.D, S.E.M., R.J.M., A.F.H., G.M.F.).
Robert J MentzDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.J.G., M.F., J.-L.S., A.D.D, S.E.M., R.J.M., A.F.H., G.M.F.).
Adrian F HernandezDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.J.G., M.F., J.-L.S., A.D.D, S.E.M., R.J.M., A.F.H., G.M.F.).
G Michael FelkerDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC (S.J.G., M.F., J.-L.S., A.D.D, S.E.M., R.J.M., A.F.H., G.M.F.).
Lauren B CooperInova Heart and Vascular Institute, Falls Church, VA (L.B.C.).
Barry A BorlaugDivision of Circulatory Failure, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.).
Eric J VelazquezYale University School of Medicine, New Haven, CT (E.J.V.).
Kenneth B MarguliesPerelman School of Medicine, University of Pennsylvania, Philadelphia (K.B.M.).
Abhinav SharmaMcGill University Health Centre, McGill University, Montreal, QC, Canada (B.R., A.S.).

Funding

NCATS NIH HHS UL1 TR002541
6 · The paper itself

Abstract

backgroundThe FIGHT (Functional Impact of GLP-1 [glucagon-like peptide-1] for Heart Failure Treatment) trial randomized 300 patients with heart failure with reduced ejection fraction (HFrEF) and a recent hospitalization for heart failure to liraglutide versus placebo. While there was no difference in the primary outcome (rank score of time to death, time to rehospitalization for heart failure, and change in NT-proBNP [N-terminal pro-B-type natriuretic peptide]), there was a significant increase in cystatin C among patients randomized to liraglutide raising concern of adverse renal outcomes. We performed a post hoc analysis of FIGHT to investigate whether liraglutide was associated with worsening renal function (WRF).

methodsThe relationship between randomization to liraglutide and WRF was evaluated using logistic regression models. Two hundred seventy-four patients (91%) had complete data to assess for WRF defined as: increase in SCr ≥0.3 mg/dL, or ≥25% decrease in estimated glomerular filtration rate, or an increase in cystatin C ≥0.3 mg/L from baseline to 180-days.

resultsPatients with WRF (n=113, 41%), compared with those without, were older, had more comorbidities, and lower utilization of guideline-directed medical treatment. Logistic regression models showed that age and baseline cystatin C levels were associated with WRF. In adjusted models, liraglutide was not associated with excess risk of WRF compared with placebo (odds ratio, 1.02 [95% CI, 0.62-1.67]). There was also no difference in the rank score when WRF was added as a fourth-tier outcome.

conclusionsLiraglutide was not associated with WRF among patients with HFrEF and a recent hospitalization for heart failure. These data support the relative renal safety profile of liraglutide among patients with HFrEF. Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01800968.

Indexed as

AgedDouble-Blind MethodFemaleGlomerular Filtration RateGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHeart FailureHospitalizationHumansIncretinsKidneyLiraglutideMaleMiddle AgedRisk AssessmentRisk FactorsGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsIncretinsLiraglutide

Identifiers

PMID32362166
PMCPMC7906045

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.